ARHGAP11B

Summary

ARHGAP11B (Rho GTPase activating protein 11B, HGNC:15782) is a protein-coding gene on chromosome 15q13.2, encoding Inactive Rho GTPase-activating protein 11B (Q3KRB8). Hominin-specific protein that promotes development and evolutionary expansion of the brain neocortex.

Predicted to enable GTPase activator activity. Involved in cerebral cortex development and negative regulation of mitochondrial membrane permeability. Acts upstream of with a positive effect on glutamine catabolic process. Located in mitochondrial matrix.

Source: NCBI Gene 89839 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 114 total — 38 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 3
• Dosage sensitivity (ClinGen): haploinsufficiency no evidence, triplosensitivity no evidence
• MANE Select transcript: NM_001039841

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15782
Approved symbol	ARHGAP11B
Name	Rho GTPase activating protein 11B
Location	15q13.2
Locus type	gene with protein product
Status	Approved
Aliases	B’-T
Ensembl gene	ENSG00000285077
Ensembl biotype	protein_coding
OMIM	616310
Entrez	89839

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 4 protein_coding_CDS_not_defined, 3 protein_coding, 1 retained_intron

ENST00000428041, ENST00000566362, ENST00000567449, ENST00000568574, ENST00000646747, ENST00000689358, ENST00000693711, ENST00000697964

RefSeq mRNA: 1 — MANE Select: NM_001039841 NM_001039841

CCDS: CCDS32185

Canonical transcript exons

ENST00000621228 — 0 exons

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 85.56.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.6927 / max 75.5587, expressed in 1037 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
145640	3.5722	997
145639	0.1205	35

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.56	gold quality
bone marrow	UBERON:0002371	77.59	gold quality
bone marrow cell	CL:0002092	75.39	gold quality
ganglionic eminence	UBERON:0004023	74.33	gold quality
stromal cell of endometrium	CL:0002255	74.17	gold quality
ventricular zone	UBERON:0003053	73.51	gold quality
endometrium	UBERON:0001295	72.94	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	72.77	gold quality
lymph node	UBERON:0000029	72.51	gold quality
monocyte	CL:0000576	72.35	gold quality
leukocyte	CL:0000738	71.97	gold quality
vermiform appendix	UBERON:0001154	70.53	gold quality
lower esophagus mucosa	UBERON:0035834	70.43	gold quality
rectum	UBERON:0001052	70.11	gold quality
tonsil	UBERON:0002372	70.07	gold quality
calcaneal tendon	UBERON:0003701	69.57	gold quality
esophagus mucosa	UBERON:0002469	68.63	gold quality
mucosa of transverse colon	UBERON:0004991	66.39	gold quality
spleen	UBERON:0002106	65.50	gold quality
smooth muscle tissue	UBERON:0001135	65.49	gold quality
granulocyte	CL:0000094	65.08	gold quality
esophagus	UBERON:0001043	64.95	gold quality
duodenum	UBERON:0002114	64.89	gold quality
small intestine Peyer’s patch	UBERON:0003454	64.34	gold quality
small intestine	UBERON:0002108	64.09	gold quality
minor salivary gland	UBERON:0001830	63.95	gold quality
transverse colon	UBERON:0001157	63.87	gold quality
adrenal tissue	UBERON:0018303	63.84	gold quality
intestine	UBERON:0000160	63.72	gold quality
vagina	UBERON:0000996	63.70	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-8271	no	93.00
E-ANND-3	no	1.71

Regulation

Is transcription factor: no

Functional genomics

ClinGen dosage: haploinsufficiency 0 (no evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 8)

• ARHGAP11B may have contributed to evolutionary expansion of human neocortex. (PMID:25721503)
• The data also demonstrate that a single C–>G base substitution underlies the ARHGAP11B-mediated basal progenitor amplification implicated in neocortex expansion. (PMID:27957544)
• Human-specific ARHGAP11B induces hallmarks of neocortical expansion in developing ferret neocortex. (PMID:30484771)
• an ARHGAP11B-induced, mitochondria-based effect on basal progenitor metabolism that is a hallmark of highly mitotically active cells appears to underlie its role in neocortex expansion. (PMID:31883789)
• Human-specific ARHGAP11B increases size and folding of primate neocortex in the fetal marmoset. (PMID:32554627)
• Expression of human-specific ARHGAP11B in mice leads to neocortex expansion and increased memory flexibility. (PMID:33938018)
• Human-specific ARHGAP11B ensures human-like basal progenitor levels in hominid cerebral organoids. (PMID:36098218)
• Protooncogenic Role of ARHGAP11A and ARHGAP11B in Invasive Ductal Carcinoma: Two Promising Breast Cancer Biomarkers. (PMID:38046902)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	arhgap11a	ENSDARG00000100019
caenorhabditis_elegans		WBGENE00019600
caenorhabditis_elegans		WBGENE00022286

Paralogs (1): ARHGAP11A (ENSG00000198826)

Protein

Protein identifiers

Inactive Rho GTPase-activating protein 11B — Q3KRB8 (reviewed: Q3KRB8)

Alternative names: Rho-type GTPase-activating protein 11B

All UniProt accessions (1): Q3KRB8

UniProt curated annotations — full annotation on UniProt →

Function. Hominin-specific protein that promotes development and evolutionary expansion of the brain neocortex. Able to promote amplification of basal progenitors in the subventricular zone, producing more neurons during fetal corticogenesis, thereby playing a key role in neocortex expansion. Promotes the proliferation of basal progenitors by inhibiting the mitochondrial permeability transition pore (mPTP): delays the opening of the mPTP via interaction with ADP:ATP translocase, thereby increasing mitochondrial Ca(2+) concentration and inducing glutamine catabolism, which is required for basal progenitor proliferation. Does not possess GTPase activator activity: the absence of GTPase activator activity is required to promote amplification of basal progenitors during neocortex development.

Subunit / interactions. Interacts with ADP:ATP translocase components SLC25A4/ANT1 and SLC25A5/ANT2.

Subcellular location. Mitochondrion matrix.

Miscellaneous. When expressed in embryonic mouse neocortex, promotes basal progenitor generation and self-renewal, and can increase cortical plate area and induce gyrification. Mice exhibit increased neocortical size and upper-layer neuron numbers persisting into adulthood. Moreover, mice display altered neurobehaviour, characterized by an increased memory flexibility and a reduced anxiety level. When expressed in the developing neocortex of the gyrencephalic ferret, strongly increases proliferative basal radial glia, a progenitor cell type thought to be instrumental for neocortical expansion, resulting in extension of the neurogenic period and an increase in upper-layer neurons. As consequence, the postnatal ferret neocortex displays increased neuron density in the upper cortical layers and expands in both the radial and tangential dimensions. Expression in fetal neocortex of the common marmoset increases the numbers of upper-layer neurons, promoting enlargement of the neocortex and inducing its folding. ARHGAP11B arose from partial duplication of ARHGAP11A on the human lineage after separation from the chimpanzee lineage, but before the divergence from Neandertals.

RefSeq proteins (1): NP_001034930* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000198	RhoGAP_dom	Domain
IPR008936	Rho_GTPase_activation_prot	Homologous_superfamily
IPR042869	ARHGAP11A/B	Family

Pfam: PF00620

UniProt features (4 total): transit peptide 1, chain 1, domain 1, site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q3KRB8-F1	77.88	0.43

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 87 (arginine finger; crucial for gtp hydrolysis by stabilizing the transition state)

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-8980692	RHOA GTPase cycle
R-HSA-9013148	CDC42 GTPase cycle

MSigDB gene sets: 58 (showing top): GOBP_ALPHA_AMINO_ACID_METABOLIC_PROCESS, chr15q13, GOBP_REGULATION_OF_GTPASE_ACTIVITY, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, GOBP_GLUTAMINE_FAMILY_AMINO_ACID_METABOLIC_PROCESS, GOBP_MITOCHONDRIAL_TRANSPORT, GOBP_FOREBRAIN_DEVELOPMENT, GOBP_GLUTAMINE_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY, GOBP_REGULATION_OF_HYDROLASE_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_CEREBRAL_CORTEX_DEVELOPMENT, FISCHER_G2_M_CELL_CYCLE, GOBP_ORGANIC_ACID_CATABOLIC_PROCESS, GOBP_PALLIUM_DEVELOPMENT

GO Biological Process (5): L-glutamine catabolic process (GO:0006543), signal transduction (GO:0007165), cerebral cortex development (GO:0021987), negative regulation of mitochondrial membrane permeability (GO:0035795), regulation of small GTPase mediated signal transduction (GO:0051056)

GO Molecular Function (2): GTPase activator activity (GO:0005096), protein binding (GO:0005515)

GO Cellular Component (3): mitochondrial matrix (GO:0005759), cytosol (GO:0005829), mitochondrion (GO:0005739)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RHO GTPase cycle	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
L-glutamine metabolic process	1
L-amino acid catabolic process	1
proteinogenic amino acid catabolic process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
pallium development	1
anatomical structure development	1
regulation of mitochondrial membrane permeability	1
negative regulation of membrane permeability	1
small GTPase-mediated signal transduction	1
regulation of intracellular signal transduction	1
GTPase activity	1
enzyme activator activity	1
GTPase regulator activity	1
binding	1
mitochondrion	1
intracellular organelle lumen	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

942 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARHGAP11B	SRGAP2C	P0DJJ0	720
ARHGAP11B	NOTCH2NLA	Q7Z3S9	672
ARHGAP11B	NOTCH2NLB	P0DPK3	669
ARHGAP11B	MTMR10	Q9NXD2	664
ARHGAP11B	TRNP1	Q6NT89	630
ARHGAP11B	OTUD7A	Q8TE49	628
ARHGAP11B	TMEM14B	Q9NUH8	609
ARHGAP11B	FAN1	Q9Y2M0	583
ARHGAP11B	CHRFAM7A	Q494W8	582
ARHGAP11B	SRGAP2B	P0DMP2	575
ARHGAP11B	FAM72C	H0Y354	514
ARHGAP11B	FAM72B	Q86X60	513
ARHGAP11B	BOLA2	Q9H3K6	479
ARHGAP11B	TCAF1	Q9Y4C2	478
ARHGAP11B	FAM72D	Q6L9T8	471

IntAct

2 interactions, top by confidence:

A	B	Type	Score
ARHGAP11B	RPN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (31): ARHGAP11B (Affinity Capture-RNA), ARHGAP11B (Affinity Capture-MS), ARHGAP11B (Affinity Capture-MS), ARHGAP11B (FRET), ARHGAP11B (FRET), CBS (Affinity Capture-MS), CSRP2 (Affinity Capture-MS), DOCK4 (Affinity Capture-MS), DUT (Affinity Capture-MS), GPX1 (Affinity Capture-MS), LSM14A (Affinity Capture-MS), MCTS1 (Affinity Capture-MS), MOB2 (Affinity Capture-MS), MTPN (Affinity Capture-MS), PCMT1 (Affinity Capture-MS)

ESM2 similar proteins: A4II46, A4IJ06, B2RQE8, D2HBJ8, O88842, O88910, O88954, O95267, P0CAX5, P55194, Q02384, Q07890, Q13368, Q14CB8, Q3KRB8, Q3LAC4, Q3U0J8, Q5BKC9, Q5E9G6, Q5F3G0, Q5RDX5, Q5U4T3, Q5XGZ2, Q62245, Q69ZK0, Q6INE5, Q6NTL4, Q6NTR6, Q6PCS4, Q6ZM89, Q6ZR37, Q6ZT62, Q70Z35, Q7Z5H3, Q7Z628, Q7Z6J4, Q8AVG0, Q8BL80, Q8BRH3, Q8BY35

Diamond homologs: A1A4S6, A6NI28, A6X8Z5, A7E300, B2RQE8, B5DFQ4, B9VTT2, D3ZFJ3, D3ZZN9, E9Q6X9, F1LQX4, O43182, O60890, P0CAX5, P15882, P30337, P55194, P81128, P83509, P98171, Q07960, Q08DP6, Q13459, Q14CB8, Q17QN0, Q17R89, Q2M1Z3, Q3KRB8, Q54FF4, Q54PG5, Q54TH9, Q54VW7, Q553X3, Q559A0, Q5FWK3, Q5SSM3, Q5TG30, Q5U4T3, Q62172, Q63358

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ARHGAP11B	“down-regulates activity”	RHOA	“gtpase-activating protein”
ARHGAP11B	“down-regulates activity”	CDC42	“gtpase-activating protein”

Disease & clinical

Clinical variants and AI predictions

ClinVar

114 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	38
Likely pathogenic	2
Uncertain significance	59
Likely benign	4
Benign	1

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1330163	GRCh37/hg19 15q13.2-13.3(chr15:30897996-32404614)x1	Pathogenic
149631	GRCh38/hg38 15q11.2-13.1(chr15:23319714-32607357)x3	Pathogenic
150297	GRCh38/hg38 15q13.2-13.3(chr15:30629714-32247465)x1	Pathogenic
152016	GRCh38/hg38 15q13.2-13.3(chr15:30527262-32222779)x1	Pathogenic
152978	GRCh38/hg38 15q13.2-13.3(chr15:30217122-32217725)x1	Pathogenic
154725	GRCh38/hg38 15q13.2-13.3(chr15:30629714-32569425)x3	Pathogenic
154741	GRCh38/hg38 15q13.2-13.3(chr15:30629714-32222779)x1	Pathogenic
155195	GRCh38/hg38 15q13.2-13.3(chr15:30629714-32275124)x1	Pathogenic
160802	GRCh38/hg38 15q13.2-13.3(chr15:30527262-32217725)x1	Pathogenic
160914	GRCh38/hg38 15q13.2-13.3(chr15:30361674-32222779)x1	Pathogenic
161076	GRCh38/hg38 15q13.2-13.3(chr15:30438310-32569425)x1	Pathogenic
1684560	GRCh37/hg19 15q13.2-13.3(chr15:30819465-32509926)x1	Pathogenic
1701266	GRCh37/hg19 15q13.2-13.3(chr15:30899058-32446187)x1	Pathogenic
1707445	GRCh37/hg19 15q13.1-13.2(chr15:30026120-31073669)x4	Pathogenic
1808682	GRCh37/hg19 15q13.2-13.3(chr15:30913574-32446830)x1	Pathogenic
2423388	NC_000015.9:g.(?30906349)(32446187_?)del	Pathogenic
2446467	GRCh37/hg19 15q13.2-13.3(chr15:30921917-32514980)x1	Pathogenic
2580300	GRCh37/hg19 15q13.2-13.3(chr15:30805785-32686484)x1	Pathogenic
2580303	GRCh37/hg19 15q13.2-13.3(chr15:30918974-32442006)x1	Pathogenic
2580311	GRCh37/hg19 15q13.2-13.3(chr15:30850097-32693726)x1	Pathogenic
2580323	GRCh37/hg19 15q13.2-13.3(chr15:30897996-32442006)x1	Pathogenic
2580334	GRCh37/hg19 15q13.2-13.3(chr15:30854238-32892694)x1	Pathogenic
3024589	GRCh37/hg19 15q13.2-13.3(chr15:30844281-32404100)x1	Pathogenic
3024590	GRCh37/hg19 15q13.2-13.3(chr15:30896376-32465219)x1	Pathogenic
33302	GRCh38/hg38 15q13.2-13.3(chr15:30527262-32217725)x1	Pathogenic
442358	GRCh37/hg19 15q13.2-13.3(chr15:30386398-32446830)x3	Pathogenic
442883	GRCh37/hg19 15q13.2-13.3(chr15:30913573-32444044)x3	Pathogenic
4796222	GRCh38/hg38 15q13.2-13.3(chr15:30094195-32151843)x1	Pathogenic
523250	GRCh37/hg19 15q13.2-13.3(chr15:30366065-32899558)	Pathogenic
545177	NC_000015.10:g.(?30325774)(32194551_?)del	Pathogenic

SpliceAI

1730 predictions. Top by Δscore:

Variant	Effect	Δscore
15:30630701:AG:A	acceptor_gain	1.0000
15:30630702:GG:G	acceptor_gain	1.0000
15:30633485:TTCAG:T	acceptor_loss	1.0000
15:30633488:A:AC	acceptor_loss	1.0000
15:30633488:A:AG	acceptor_gain	1.0000
15:30633489:G:GG	acceptor_gain	1.0000
15:30633489:GC:G	acceptor_gain	1.0000
15:30633489:GCT:G	acceptor_gain	1.0000
15:30633489:GCTT:G	acceptor_gain	1.0000
15:30633489:GCTTT:G	acceptor_gain	1.0000
15:30633582:TAAAG:T	donor_gain	1.0000
15:30633584:AAG:A	donor_gain	1.0000
15:30633585:AG:A	donor_gain	1.0000
15:30633586:GG:G	donor_gain	1.0000
15:30633586:GGT:G	donor_loss	1.0000
15:30633587:G:GG	donor_gain	1.0000
15:30634168:A:AG	acceptor_gain	1.0000
15:30634169:G:GG	acceptor_gain	1.0000
15:30635042:C:G	acceptor_gain	1.0000
15:30635046:T:TA	acceptor_gain	1.0000
15:30635057:A:AG	acceptor_gain	1.0000
15:30635058:A:G	acceptor_gain	1.0000
15:30635078:A:AG	acceptor_gain	1.0000
15:30635079:G:GG	acceptor_gain	1.0000
15:30635185:GAAG:G	donor_gain	1.0000
15:30635476:T:G	acceptor_gain	1.0000
15:30635481:A:AG	acceptor_gain	1.0000
15:30635482:T:G	acceptor_gain	1.0000
15:30635482:TTTA:T	acceptor_loss	1.0000
15:30635483:TTAG:T	acceptor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000351063 (15:30641721 T>A,C), RS1000354996 (15:30641519 T>C), RS1000467266 (15:30634573 G>T), RS1000575387 (15:30648558 A>G,T), RS1000750308 (15:30632924 A>G), RS1000819585 (15:30634965 A>G), RS1000867529 (15:30637322 T>C), RS1001088225 (15:30639850 C>T), RS1001158834 (15:30629805 C>T), RS1001165393 (15:30628935 C>A), RS1001520703 (15:30641986 G>C), RS1001573183 (15:30641804 C>T), RS1001707761 (15:30635650 T>C), RS1001719391 (15:30628693 T>C), RS1001771882 (15:30628448 G>A,C)

Disease associations

OMIM: gene MIM:616310 | disease phenotypes: MIM:612001, MIM:189800, MIM:181500, MIM:209850

GenCC curated gene-disease

Mondo (5): chromosome 15q13.3 microdeletion syndrome (MONDO:0012774), preeclampsia (MONDO:0005081), ptosis (MONDO:0000728), schizophrenia (MONDO:0005090), autism (MONDO:0005260)

Orphanet (3): 15q13.3 microdeletion syndrome (Orphanet:199318), Preeclampsia (Orphanet:275555), NON RARE IN EUROPE: Schizophrenia (Orphanet:3140)

HPO phenotypes

3 total (3 of 3 shown, HPO-id order):

HPO	Term
HP:0000508	Ptosis
HP:0100753	Schizophrenia
HP:0000717	Autism

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002141_7	Epilepsy (remission after treatment)	3.000000e-06

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500
D001763	Blepharoptosis	C11.338.204
D011225	Pre-Eclampsia	C12.050.703.395.249
C567439	Chromosome 15q13.3 Microdeletion Syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression	2
methylmercuric chloride	increases expression	1
propionaldehyde	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, decreases expression	1
jinfukang	increases expression	1
incobotulinumtoxinA	decreases expression	1
(+)-JQ1 compound	decreases expression	1
Acetaminophen	increases expression	1
Cadmium	decreases expression, increases abundance	1
Calcitriol	decreases expression, affects cotreatment	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Dimethyl Sulfoxide	affects expression	1
Drugs, Chinese Herbal	decreases expression	1
Lipopolysaccharides	decreases expression, decreases reaction	1
Lucanthone	decreases expression	1
Testosterone	affects cotreatment, decreases expression	1
Dronabinol	increases expression	1
Tretinoin	decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
S-Nitrosoglutathione	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_C0IF	WYUi001-A	Induced pluripotent stem cell	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00117546	PHASE4	UNKNOWN	Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
NCT00567957	PHASE4	UNKNOWN	Remifentanil for General Anesthesia in Preeclamptics
NCT01030627	PHASE4	COMPLETED	Treatment Approaches to Preeclampsia
NCT01352234	PHASE4	COMPLETED	Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
NCT01361425	PHASE4	UNKNOWN	Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)
NCT01729468	PHASE4	COMPLETED	Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers
NCT01761916	PHASE4	COMPLETED	Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure
NCT01912677	PHASE4	COMPLETED	Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
NCT02025426	PHASE4	TERMINATED	Phenylephrine Versus Ephedrine in Pre-eclampsia
NCT02091401	PHASE4	COMPLETED	A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen
NCT02163655	PHASE4	COMPLETED	Diuretics for Postpartum High Blood Pressure in Preeclampsia
NCT02338687	PHASE4	COMPLETED	Low Dose Calcium to Prevent Preeclampsia
NCT02396030	PHASE4	TERMINATED	Different Schemes of Magnesium Sulfate for Preeclampsia
NCT02531490	PHASE4	UNKNOWN	Early Vascular Adjustments During Hypertensive Pregnancy
NCT02699827	PHASE4	COMPLETED	Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia
NCT02835339	PHASE4	COMPLETED	Magnesium Sulfate in Obese Preeclamptics
NCT02891174	PHASE4	COMPLETED	The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy
NCT02911701	PHASE4	COMPLETED	Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
NCT03171480	PHASE4	COMPLETED	Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
NCT03233880	PHASE4	UNKNOWN	Impact of Antichlamydial Treatment on the Rate of Preeclampsia
NCT03237000	PHASE4	UNKNOWN	Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
NCT03506724	PHASE4	COMPLETED	Response to Anti-hypertensives in Pregnant and Postpartum Patients
NCT03674606	PHASE4	COMPLETED	Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
NCT03735433	PHASE4	TERMINATED	The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
NCT03824119	PHASE4	UNKNOWN	Postpartum NSAIDS and Maternal Hypertension
NCT04051567	PHASE4	UNKNOWN	Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies
NCT04077853	PHASE4	COMPLETED	Progesterone in Expectantly Managed Early-onset Preeclampsia
NCT04158830	PHASE4	WITHDRAWN	Aspirin (ASA) Therapy and Preeclampsia Prevention
NCT04424693	PHASE4	UNKNOWN	Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
NCT04631627	PHASE4	UNKNOWN	Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
NCT04656665	PHASE4	UNKNOWN	The Effectiveness of Aspirin on Preventing Pre-eclampsia
NCT04797949	PHASE4	WITHDRAWN	Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
NCT04908982	PHASE4	UNKNOWN	Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension
NCT05221164	PHASE4	UNKNOWN	162 mg of Aspirin for Prevention of Preeclampsia
NCT05294952	PHASE4	UNKNOWN	co Ihibtory Receptor in Preeclampsia
NCT05514847	PHASE4	ACTIVE_NOT_RECRUITING	Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
NCT05586373	PHASE4	COMPLETED	Ibuprofen vs Dipyrone After C-section in Preeclampsia
NCT06069102	PHASE4	COMPLETED	Optimal Blood Pressure Treatment Thresholds Postpartum
NCT06107335	PHASE4	NOT_YET_RECRUITING	Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia
NCT06281665	PHASE4	RECRUITING	Treatment With Aspirin After Preeclampsia: TAP Trial